Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticosteroids plus adalimumab biosimilar vs corticosteroids plus immunosuppressants for non-infectious uveitis
ChiCTR2600123180Phase 4Recruiting
- Sponsor
- Shenzhen Eye Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab in noninfectious uveitis (NIU), Hyalitis, posterior uveitis and 1 more (2 arms), sponsored by Shenzhen Eye Hospital. Primary endpoint: Change in BCVA (ETDRS letters) at week 24. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
noninfectious uveitis (NIU)Hyalitisposterior uveitispanuveitis
Beyond the preview
Go deeper on ChiCTR2600123180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123180.